NexGel (NXGL) Q1 2026 earnings show $2.65M revenue, acquisition impacts, and future growth potential. Management projects $35M annual revenue post-acquisition.

Key Takeaways

• Q1 2026 revenue totaled $2.65 million, a decrease from $2.81 million year-over-year.
• The company raised $13.8 million to support its acquisition strategy and working capital.
• Management anticipates a threefold increase in annual revenue post-acquisition, targeting $35 million.
• Operating expenses are expected to rise to an approximate monthly run rate of $500,000.
• Cash on hand as of March 31, 2026, stood at $1.8 million.

Financial Performance

NexGel, Inc reported its first-quarter 2026 financial results, highlighting a revenue of $2.65 million, which reflects a decline from $2.81 million recorded in the same period last year. The company noted that this relatively flat performance was primarily due to lower sales from its Silly George brand, although this was partially offset by growth in contract manufacturing and its Med Gel brand.

The company's selling, general, and administrative (SGA) expenses increased, largely attributed to costs related to the acquisition of the Bionics division and the settlement of the Kiss Nail Products legal case. As of the end of the first quarter, NexGel's cash and restricted cash totaled approximately $2.1 million, with a current cash position of $1.8 million. The company successfully raised $13.8 million, comprising $8.8 million in cash and $5 million from a convertible note to facilitate the acquisition and bolster working capital.

Strategic Initiatives

A significant focus of the earnings call was the integration of the recently acquired Bionics division. The acquisition, which closed in mid-April, positions NexGel strategically within the regenerative biomaterials market, encompassing a portfolio of six commercial-stage products that have been utilized in over 500 hospitals across the U.S. Management emphasized that this acquisition is expected to provide immediate revenue and profitability benefits, with projections indicating a potential annual revenue boost to $35 million upon full integration.

The partnership with Sequence Life Science, which led the financing for the acquisition with a $5.5 million investment, is expected to enhance NexGel's manufacturing, product development, and distribution capabilities. The addition of industry veterans Brian J. Keizer and Kevin Harris to the board is seen as a strategic move to leverage their expertise in scaling operations and accelerating growth.

Furthermore, the company is actively expanding its sales force, having appointed Dave Hazard as Vice President of Sales for Bionic Surgical. Hazard's extensive experience in orthopedics and biologics is anticipated to drive significant revenue growth as the new division ramps up its operations.

Future Outlook

Looking ahead, NexGel management expressed optimism about the recovery of sales in the Silly George product line, which had faced challenges in the previous quarters. They noted signs of improvement in sales as of April and expect continued growth in both contract manufacturing and Medi Gel products.

The company has introduced three 510k devices in development, with commercialization targeted for 2026, 2027, and 2028, representing an investment of approximately $4.6 million. Management reiterated their commitment to building a robust platform for long-term growth and profitability, anticipating that the integration of Bionics will significantly contribute to this goal.

While operating expenses are projected to increase to an approximate monthly run rate of $500,000, the company expects these investments will facilitate sustained revenue growth. The management aims to provide further updates on integration and performance in their next earnings call scheduled for August, where they will delve deeper into the accomplishments and future targets of the Bionics division.

Closing Assessment

In summary, NexGel, Inc is navigating a transformative phase marked by a strategic acquisition and the potential for significant revenue growth. While facing some challenges in the first quarter, the company's proactive initiatives to integrate its new assets and enhance its product lineup could position them favorably in the regenerative medicine market. Investors are encouraged to monitor the company’s progress as it works to establish a stronger foothold in this rapidly evolving industry.

This analysis is based on public earnings call materials and is not investment advice.